Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC)
EUR 62.05
(0.98%)
EUR 62.05
(0.98%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 52.24 Million EUR | -12.11% |
| 2022 | 59.44 Million EUR | -10.94% |
| 2021 | 66.74 Million EUR | -2.45% |
| 2020 | 68.42 Million EUR | -5.11% |
| 2019 | 72.1 Million EUR | 334.65% |
| 2018 | 16.58 Million EUR | -38.63% |
| 2017 | 27.02 Million EUR | 29.77% |
| 2016 | 20.82 Million EUR | -36.17% |
| 2015 | 32.63 Million EUR | 1.87% |
| 2014 | 32.03 Million EUR | 41.87% |
| 2013 | 22.57 Million EUR | -22.51% |
| 2012 | 29.13 Million EUR | -29.36% |
| 2011 | 41.24 Million EUR | -4.28% |
| 2010 | 43.08 Million EUR | 72.8% |
| 2009 | 24.93 Million EUR | -13.05% |
| 2008 | 28.67 Million EUR | 29.31% |
| 2007 | 22.17 Million EUR | 82.29% |
| 2006 | 12.16 Million EUR | 0.0% |
| 2005 | - EUR | 0.0% |
| 2004 | - EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 59.62 Million EUR | 54.58% |
| 2024 Q2 | 98.14 Million EUR | -100.0% |
| 2023 Q1 | 56.87 Million EUR | -4.31% |
| 2023 Q4 | 52.24 Million EUR | 0.32% |
| 2023 Q3 | 52.07 Million EUR | -4.52% |
| 2023 Q2 | 54.54 Million EUR | -4.11% |
| 2023 FY | 52.24 Million EUR | -12.11% |
| 2022 FY | 59.44 Million EUR | -10.94% |
| 2022 Q2 | 66.37 Million EUR | 0.47% |
| 2022 Q4 | 59.44 Million EUR | -11.03% |
| 2022 Q1 | 66.06 Million EUR | -1.02% |
| 2022 Q3 | 66.8 Million EUR | 0.65% |
| 2021 Q3 | 66.67 Million EUR | -0.85% |
| 2021 FY | 66.74 Million EUR | -2.45% |
| 2021 Q4 | 66.74 Million EUR | 0.1% |
| 2021 Q2 | 67.24 Million EUR | -0.2% |
| 2021 Q1 | 67.38 Million EUR | -1.52% |
| 2020 Q3 | 68.89 Million EUR | -0.99% |
| 2020 Q4 | 68.42 Million EUR | -0.69% |
| 2020 Q1 | 71.21 Million EUR | -1.23% |
| 2020 Q2 | 69.58 Million EUR | -2.29% |
| 2020 FY | 68.42 Million EUR | -5.11% |
| 2019 FY | 72.1 Million EUR | 334.65% |
| 2019 Q3 | 33.46 Million EUR | -2.89% |
| 2019 Q1 | 33.3 Million EUR | 100.74% |
| 2019 Q2 | 34.45 Million EUR | 3.48% |
| 2019 Q4 | 72.1 Million EUR | 115.47% |
| 2018 Q1 | 22.28 Million EUR | -17.55% |
| 2018 Q2 | 19.38 Million EUR | -13.0% |
| 2018 FY | 16.58 Million EUR | -38.63% |
| 2018 Q4 | 16.58 Million EUR | -19.63% |
| 2018 Q3 | 20.64 Million EUR | 6.45% |
| 2017 FY | 27.02 Million EUR | 29.77% |
| 2017 Q4 | 27.02 Million EUR | -17.6% |
| 2017 Q3 | 32.8 Million EUR | -9.17% |
| 2017 Q2 | 36.11 Million EUR | -5.71% |
| 2017 Q1 | 38.29 Million EUR | 83.88% |
| 2016 Q3 | 24.27 Million EUR | -10.26% |
| 2016 Q2 | 27.05 Million EUR | -9.72% |
| 2016 Q4 | 20.82 Million EUR | -14.2% |
| 2016 Q1 | 29.96 Million EUR | -8.18% |
| 2016 FY | 20.82 Million EUR | -36.17% |
| 2015 Q1 | 30.99 Million EUR | -3.25% |
| 2015 FY | 32.63 Million EUR | 1.87% |
| 2015 Q4 | 32.63 Million EUR | -9.12% |
| 2015 Q3 | 35.9 Million EUR | 22.99% |
| 2015 Q2 | 29.19 Million EUR | -5.8% |
| 2014 Q1 | 21.51 Million EUR | -4.73% |
| 2014 Q4 | 32.03 Million EUR | -2.59% |
| 2014 Q2 | 20.92 Million EUR | -2.71% |
| 2014 Q3 | 32.88 Million EUR | 57.13% |
| 2014 FY | 32.03 Million EUR | 41.87% |
| 2013 Q4 | 22.57 Million EUR | -1.41% |
| 2013 Q3 | 22.9 Million EUR | -3.15% |
| 2013 FY | 22.57 Million EUR | -22.51% |
| 2013 Q2 | 23.64 Million EUR | -17.74% |
| 2013 Q1 | 28.74 Million EUR | -1.32% |
| 2012 Q1 | 35.81 Million EUR | -13.18% |
| 2012 Q2 | 1.77 Million EUR | -95.03% |
| 2012 Q3 | 29.73 Million EUR | 1571.44% |
| 2012 FY | 29.13 Million EUR | -29.36% |
| 2012 Q4 | 29.13 Million EUR | -2.02% |
| 2011 FY | 41.24 Million EUR | -4.28% |
| 2011 Q1 | 45.42 Million EUR | 5.43% |
| 2011 Q2 | 43.71 Million EUR | -3.76% |
| 2011 Q3 | 43.3 Million EUR | -0.95% |
| 2011 Q4 | 41.24 Million EUR | -4.75% |
| 2010 Q4 | 43.08 Million EUR | 0.0% |
| 2010 FY | 43.08 Million EUR | 72.8% |
| 2009 FY | 24.93 Million EUR | -13.05% |
| 2008 FY | 28.67 Million EUR | 29.31% |
| 2007 FY | 22.17 Million EUR | 82.29% |
| 2006 FY | 12.16 Million EUR | 0.0% |
| 2005 FY | - EUR | 0.0% |
| 2004 FY | - EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Atrys Health, S.A. | 162.72 Million EUR | 67.896% |
| Biotechnologies Assets SA | 5.15 Million EUR | -913.583% |
| Pharma Mar, S.A. | 27.03 Million EUR | -93.231% |